Stephen A. Sherwin - 05 Jun 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
09 Jun 2026, 17:40:34 UTC
Prior SEC filing
29 May 2026
Next SEC filing
11 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Stephen A. Sherwin filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 09 Jun 2026.

Key facts

  • This page summarizes Stephen A. Sherwin's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
  • 9 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 09 Jun 2026, 17:40.

Change

  • Previous filing in this sequence was filed on 29 May 2026.
  • Current net transaction value: -$4,132,969.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001079462 Primary reporting owner

SHERWIN STEPHEN A

Relationship
Director
Address
6027 EDGEWOOD BEND CT., SAN DIEGO
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Signature date
09 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Options Exercise

Transaction value
Shares
+15,000
Change %
+95%
Price
$53.64*
Shares after
30,860
Date
05 Jun 2026
Ownership
Direct
NBIX transaction

Common Stock

Options Exercise

Transaction value
Shares
+10,000
Change %
+32%
Price
$79.79*
Shares after
40,860
Date
05 Jun 2026
Ownership
Direct
NBIX transaction

Common Stock

Sale

Transaction value
$1,291,291
Shares
-7,883
Change %
-19%
Price
$163.81
Shares after
32,977
Date
05 Jun 2026
Ownership
Direct
Footnotes
F1, F2
NBIX transaction

Common Stock

Sale

Transaction value
$419,156
Shares
-2,549
Change %
-7.7%
Price
$164.44
Shares after
30,428
Date
05 Jun 2026
Ownership
Direct
Footnotes
F1, F3
NBIX transaction

Common Stock

Sale

Transaction value
$1,143,306
Shares
-6,896
Change %
-23%
Price
$165.79
Shares after
23,532
Date
05 Jun 2026
Ownership
Direct
Footnotes
F1, F4
NBIX transaction

Common Stock

Sale

Transaction value
$970,859
Shares
-5,829
Change %
-25%
Price
$166.56
Shares after
17,703
Date
05 Jun 2026
Ownership
Direct
Footnotes
F1, F5
NBIX transaction

Common Stock

Sale

Transaction value
$308,357
Shares
-1,843
Change %
-10%
Price
$167.31
Shares after
15,860
Date
05 Jun 2026
Ownership
Direct
Footnotes
F1, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX transaction Derivative

Non-Qualified Stock Option

Options Exercise

Transaction value
Shares
-15,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
05 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,000
Exercise price
$53.64
Footnotes
F7
NBIX transaction Derivative

Non-Qualified Stock Option

Options Exercise

Transaction value
Shares
-10,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
05 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
$79.79
Footnotes
F8
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 8 footnotes

Footnote F1

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Footnote F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.11 to $164.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F3

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.11 to $164.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F4

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.11 to $166.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F5

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.11 to $167.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F6

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.11 to $167.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F7

The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017.

Footnote F8

The option was granted May 22, 2019 and vested in 12 equal monthly installments beginning June 22, 2019.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .